Interferon-γ causes myogenic cell dysfunction and senescence in immune myopathies
Brain · 01.08.2025 · 148 (8) · 2883-2898
DOI: 10.1093/brain/awaf153 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 29.04.2025. Verfasst von Cyrielle Hou und 12 weiteren Autor:innen. Beteiligte Einrichtung: IMRB U955-Team Relaix, Paris Est Créteil University, INSERM, Créteil F-94010, France. Hauptthemen laut MEDLINE: Interferon-gamma, Cellular Senescence, Myositis, Myositis, Inclusion Body. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Association Française contre les Myopathies, TRANSLAMUSCLE, Agence Nationale pour la Recherche.
Abstract (Originalsprache)
Idiopathic immune myopathies (IIM) represent a heterogeneous group of diseases, in which muscle lesions result from deregulated immune reactions. Typical histological features include myofibre necrosis, leucocyte infiltration and aberrant myofibre major histocompatibility complex (MHC) expression. To investigate the link between MHC expression, inflammation and muscle lesions, muscle biopsies from IIM patients were analysed by transcriptomics. Both anti-synthetase syndrome (ASS) and inclusion body myositis (IBM) displayed the upregulation of interferon-γ (IFN-γ) and senescence signalling pathways. Notably, IFN-γ expression significantly correlated with myofibre atrophy in ASS and IBM muscle biopsies. In addition to MHC-II expression at the myofibre sarcolemma in IBM, we observed a marked overexpression in the muscle stem cell (MuSC) population, suggesting that resident satellite cells respond to IFN-γ in this condition. To examine the link between IFN-γ and muscle atrophy via MuSCs, we implanted an osmotic pump chronically releasing recombinant mouse IFN-γ in wild-type mice subjected to acute muscle injury. Under IFN-γ exposure, post-injury muscle repair was associated with significantly reduced muscle weight and myofibre diameter, while promoting interstitial fibrosis and fat deposition. The mechanism of action of the IFN-γ-induced myofibre atrophy was further investigated in vitro using cultured human MuSCs. IFN-γ stimulation dramatically impaired MuSC proliferation, fusion and promoted cell senescence. Isolated myofibres from IFN-γ-treated wild-type mice displayed a significant decrease of myogenic regulatory factor MyoD expression and cell cycling, suggesting that IFN-γ also prevents MuSC activation. In vitro, ruxolitinib, a commercially available Janus kinase (JAK)1/2 antagonist, blocked IFN-γ-induced expression of MHC-II, restored normal MuSC proliferation and reduced β-galactosidase activity, a marker of cell senescence. In vivo, oral delivery of ruxolitinib improved myofibre size and biomarkers of muscle atrophy. Our study provides multiple lines of evidence that IFN-γ may mediate muscle atrophy in IBM patients. The identified mechanism of action involves JAK1/2 pathways, which impair MuSC function by preventing post-lesion myogenesis and promoting cell senescence. Our data suggest that repurposing JAK1/2 inhibitors may offer a new therapeutic option for treating IBM, a condition known for its resistance to classical immunosuppressant drugs, despite their effectiveness in other IIM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IMRB U955-Team Relaix, Paris Est Créteil University, INSERM, Créteil F-94010, France.
- Reference Centre for Neuromuscular Diseases 'Nord-Est-Ile de France', Créteil F-94010, France.
- AP-HP, Henri Mondor University Hospital, Pathology Department, Créteil F-94010, France.
ORCID-Profile: François-Jérôme Authier
Förderung
- Association Française contre les Myopathies
- TRANSLAMUSCLE
- Agence Nationale pour la Recherche
- RHU CARMMA
- MYOCILINF-2023
- Région Ile-de-France ARDOC Fellowship
- Société Française de Myologie
Zitieren
APA
Hou, C., Periou, B., Gervais, M., Martin, L., Berthier, J., Baba-Amer, Y., Souvannanorath, S., Lechapt-Zalcman, E., Malfatti, E., Gherardi, R. K., Relaix, F., Bencze, M., & Authier, F. J. (2025). Interferon-γ causes myogenic cell dysfunction and senescence in immune myopathies. Brain, 148(8), 2883-2898. https://doi.org/10.1093/brain/awaf153
Vancouver
Hou C, Periou B, Gervais M, Martin L, Berthier J, Baba-Amer Y, et al. Interferon-γ causes myogenic cell dysfunction and senescence in immune myopathies. Brain. 2025;148(8):2883-2898. doi:10.1093/brain/awaf153
BibTeX
@article{Hou2025,
author = {Hou, Cyrielle and Periou, Baptiste and Gervais, Marianne and Martin, Ludovic and Berthier, Juliette and Baba-Amer, Yasmine and Souvannanorath, Sarah and Lechapt-Zalcman, Emmanuele and Malfatti, Edoardo and Gherardi, Romain K and Relaix, Fréderic and Bencze, Maximilien and Authier, François-Jérôme},
title = {Interferon-γ causes myogenic cell dysfunction and senescence in immune myopathies},
journal = {Brain},
year = {2025},
volume = {148},
number = {8},
pages = {2883--2898},
doi = {10.1093/brain/awaf153}
}
EUVIMED